KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.311 $0.311 Friday, 27th Jan 2023 TYME stock ended at $0.311. During the day the stock fluctuated 0% from a day low at $0.311 to a day high of $0.311.
90 days $0.311 $0.311
52 weeks $0.219 $0.405

Historical Tyme Technologies Inc prices

Date Open High Low Close Volume
Mar 07, 2022 $0.291 $0.300 $0.291 $0.291 573 600
Mar 04, 2022 $0.302 $0.316 $0.295 $0.295 453 500
Mar 03, 2022 $0.310 $0.320 $0.306 $0.308 410 400
Mar 02, 2022 $0.320 $0.324 $0.306 $0.315 650 100
Mar 01, 2022 $0.315 $0.337 $0.310 $0.315 626 300
Feb 28, 2022 $0.312 $0.324 $0.304 $0.309 814 300
Feb 25, 2022 $0.310 $0.314 $0.290 $0.308 518 600
Feb 24, 2022 $0.300 $0.311 $0.280 $0.302 1 100 100
Feb 23, 2022 $0.320 $0.328 $0.301 $0.305 455 200
Feb 22, 2022 $0.336 $0.336 $0.308 $0.312 598 600
Feb 18, 2022 $0.348 $0.348 $0.331 $0.340 529 600
Feb 17, 2022 $0.340 $0.358 $0.336 $0.341 740 400
Feb 16, 2022 $0.349 $0.350 $0.336 $0.338 598 400
Feb 15, 2022 $0.328 $0.344 $0.322 $0.336 931 200
Feb 14, 2022 $0.331 $0.340 $0.320 $0.322 343 500
Feb 11, 2022 $0.360 $0.363 $0.326 $0.337 592 300
Feb 10, 2022 $0.355 $0.374 $0.350 $0.352 1 065 500
Feb 09, 2022 $0.353 $0.370 $0.353 $0.357 933 600
Feb 08, 2022 $0.370 $0.372 $0.351 $0.360 395 900
Feb 07, 2022 $0.361 $0.382 $0.344 $0.370 1 188 600
Feb 04, 2022 $0.348 $0.365 $0.329 $0.357 863 700
Feb 03, 2022 $0.370 $0.370 $0.329 $0.333 769 700
Feb 02, 2022 $0.379 $0.388 $0.350 $0.350 738 500
Feb 01, 2022 $0.358 $0.398 $0.350 $0.375 1 331 200
Jan 31, 2022 $0.330 $0.357 $0.323 $0.357 1 897 200
Click to get the best stock tips daily for free!

About Tyme Technologies Inc

Tyme Technologies Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the ... TYME Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT